US · Healthcare · Biotechnology
EPS came in at -0.35 against a street estimate of -0.34 — a miss of 2.9%.
Analysts rate PolyPid a strong buy (5 buy, 0 hold, 0 sell out of 5) with an average price target of $11.40.
| Fund | Stake |
|---|---|
| AIGH Capital Management, LLC | 7.41% |
| Rosalind Advisors, Inc. | 1.92% |
| Dafna Capital Management LLC | 1.02% |
| Morgan Stanley - Brokerage Accounts | 0.61% |
| Renaissance Technologies Corp | 0.57% |
| Marshall Wace Asset Management Ltd | 0.57% |
| ADAR1 Capital Management LLC | 0.51% |
| Symmetry Peak Management LLC | 0.50% |
Technicals, trade setups with a published hit rate, AI analysis and earnings-call summaries for PolyPid — free to start.
Open in the appGoogle PlayApp StoreData updated 2026-11-07.